SANEGENEBIO

SANEGENEBIO, founded in early 2021, is a biopharmaceutical company dedicated to developing novel small nucleic acid drugs based on RNA interference (RNAi) technology, with research and development centers in both China and the United States. The founding team consists of senior experts in the field of nucleic acid drugs, possessing years of experience in nucleic acid drug development and cutting-edge technical capabilities within the industry. Since its establishment, the company has successfully built a globally leading nucleic acid drug platform with proprietary intellectual property, encompassing chemical modification and delivery technologies for both intrahepatic and extrahepatic applications. This accelerates the development of RNAi drugs with differentiated advantages. Two core products have entered clinical trials, while multiple pipelines are progressing simultaneously, covering disease areas such as cardiovascular and cerebrovascular diseases, metabolic disorders, immune-mediated diseases, and neurological conditions. SANEGENEBIO is committed to scientific innovation, creating novel RNAi drugs to address unmet global medical needs and benefit patients and their families.